• Athena Neurosciences

    Pharmaceuticals for neurological diseases

    Acquired by Elan Corp., plc
  • Avidia

    New protein structural motifs for treating human disease.

    Acquired by Amgen
  • Calithera Biosciences

    A new class of anti-cancer therapeutics based on activation of caspases

  • Catalyst Biosciences

    Developer of engineered proteases as protein therapeutics that attack targets which cause disease.

  • Elcelyx Therapeutics

    Elcelyx is a biotechnology company that is creating new therapeutics for the treatment of diabetes and obesity

  • FoldRx Pharmaceuticals

    Treatments for diseases caused by misfolding of specific proteins

    Acquired by Pfizer
  • Galleon Pharmaceuticals

    Innovative medicines for pulmonology, neurology, cardiology, sleep medicine and pediatrics

  • GlobeImmune

    Therapeutic vaccine platform technology targeting infectious disease and cancer

  • Morphotek, Inc.

    Next generation antibodies production technology.

    Acquired by EISIA
  • Mosaic Biosciences

    Platform for tissue engineering using synthetic smart polymers

  • OncoMed Pharmaceuticals Inc.

    Biological therapeutics targeting cancer stem cells

  • Orexigen

    Developer of drug treatments for obesity and related disorders.

  • Principia

    Drug discovery company based on a proprietary chemistry platform that generates novel compounds with enhanced selectivity, high potency and longer duration of effect

  • PromediorOct2012

    Promedior Pharmaceuticals

    Therapeutics to treat fibrosis

  • Ra Pharmaceuticals

    Platform for orally available and cell permeable biologics

  • Replidyne

    Drug discovery and development focused on a new class of antibiotics

  • Ribozyme Pharmaceuticals

    RNA-based pharmaceuticals for human disease

  • Sequana Therapeutics

    Gene discovery via functional genomics

    Acquired by Axys Pharmaceutical
  • Stemgent

    Reagents for stem cell researchers

  • Threshold Pharmaceutical, Inc.

    Developing targeted therapies for treatment of cancer.

  • Tragara Pharmaceuticals

    Developer of drugs for the treatment of cancer and inflammation-related diseases.

  • Trellis Bioscience

    Platform technology for monoclonal antibody development and production

  • Vical

    DNA-based pharmaceuticals for human disease


All portfolio companies in active funds